Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T13460 |
(+)-Cevimeline hydrochloride hemihydrate
(+)-AF102B hydrochloride hemihydrate,(+)-SNI-2011 |
Others | Others |
(+)-Cevimeline hydrochloride hemihydrate ((+)-SNI-2011) 是一种有效的 mAChR 激动剂。 | |||
T13421 |
(-)-Cevimeline hydrochloride hemihydrate
(-)-SNI-2011,(-)-AF102B hydrochloride hemihydrate |
ALK | Angiogenesis; Tyrosine Kinase/Adaptors |
(-)-Cevimeline hydrochloride hemihydrate ((-)-SNI-2011) 是一种新型mAChR 激动剂,是一种治疗干燥综合征口干症的候选治疗药物。 | |||
T2390 |
Cevimeline hydrochloride hemihydrate
|
AChR | Neuroscience |
Cevimeline hydrochloride hemihydrate 是乙酰胆碱的奎尼丁衍生物,也是选择性的和口服活性的毒蕈碱型M1和M3受体激动剂。它可穿过血脑屏障,刺激唾液腺分泌,用作口干症的催涎剂。 | |||
T21119 |
Cevimeline
AF-102B,西维美林,FKS 508,SNI 2011,HSDB 7286 |
||
Cevimeline, a parasympathomimetic and muscarinic agonist, affects M1 and M3 receptors. Cevimeline has been shown to treat dry mouth and Sj gren's syndrome. It is also used to reduce Xerostomia symptoms and increase salivary flow in head and neck cancer survivors after radiotherapy. |